Modulation of Phagocytosis of Apoptotic Neutrophils by Supernatant from Dexamethasone-Treated Macrophages and Annexin-Derived Peptide AcDexamethasone-Treated Macrophages and Annexin-Derived Peptide AcDexamethasone-Treated Macrophages and Annexin-Derived Peptide Ac

Paola Maderna, Simon Yona, Mauro Perretti and Catherine Godson

J Immunol 2005; 174:3727-3733; doi: 10.4049/jimmunol.174.6.3727

http://www.jimmunol.org/content/174/6/3727

Why The JI?

- Rapid Reviews! 30 days* from submission to initial decision
- No Triage! Every submission reviewed by practicing scientists
- Speedy Publication! 4 weeks from acceptance to publication

References This article cites 49 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/174/6/3727.full#ref-list-1

Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription

Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts

The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2005 by The American Association of Immunologists All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
Phagocytic clearance of apoptotic leukocytes plays an important role in the resolution of inflammation. The glucocorticoid-inducible protein annexin I and annexin I-derived peptides show potent anti-inflammatory responses in acute and chronic inflammation. In this study, we report that the annexin I-derived peptide (Ac2–26) significantly stimulates nonphlogistic phagocytosis of apoptotic polymorphonuclear leukocytes (PMNs) by human monocyte-derived macrophages (MΦ). Peptide Ac2–26-stimulated phagocytosis is accompanied by rearrangement of the MΦ actin cytoskeleton. To investigate the potential role of endogenous annexin on clearance of apoptotic cells, MΦ were cultured for 5 days in the presence of dexamethasone. Supernatants collected from dexamethasone-treated MΦ significantly enhanced the ability of naive MΦ to engulf apoptotic PMNs. This effect was blocked by an annexin blocking Ab, by immunodepletion of the supernatants, and by the formyl peptide receptor/lipoxin receptor antagonist Boc1. In addition, we show that bone marrow-derived MΦ from annexin I-null mice present a 40% decreased phagocytosis of apoptotic PMNs compared with cells taken from littermate controls. In conclusion, these results emphasize the pivotal role of annexin I as mediator for clearance of apoptotic cells and expand its potential therapeutic role in controlling inflammatory diseases. The Journal of Immunology, 2005, 174: 3727–3733.

It is increasingly appreciated that macrophage (MΦ) phagocytosis of apoptotic cells plays an important role in the resolution of inflammation protecting tissue from harmful exposure to the inflammatory and immunogenic contents of dying cells (1–3). Should cells die by necrosis and disintegrate in situ, release of their contents may exacerbate the local inflammatory response and trigger further leukocyte influx. In addition to removing cells before they undergo lysis, it is proposed that ingestion of apoptotic cells (1–3). Should cells die by necrosis and disintegrate in situ, release of their contents may exacerbate the local inflammatory response and trigger further leukocyte influx. In addition to removing cells before they undergo lysis, it is proposed that ingestion of apoptotic cells results in potent anti-inflammatory and immunosuppressive effects through the production of anti-inflammatory cytokines such as TGF-β1 and PGE2 and the suppression of release of proinflammatory mediators (4, 5). In this context, endogenous and exogenous regulators of this process may have therapeutic potential (6). We have previously demonstrated that endogenously produced lipoxin (LX), LXA4 and LXB4, and stable LX synthetic analogs can promote nonphlogistic phagocytosis of apoptotic polymorphonuclear leukocytes (PMNs) by human monocyte-derived MΦ in vitro (7) and in vivo (8). This phagocytic effect seems to be coupled to LX-mediated alterations of the MΦ actin cytoskeleton (9) and further expands on the potential proresolving bioactivities of LXs (10, 11).

In this study, we have investigated whether a peptide mimetic of annexin I, Ac2–26, a recently described agonist for the LXA4 receptor (ALXR) (12, 13) can promote phagocytosis of apoptotic leukocytes. Annexin I is a glucocorticoid-inducible protein (14) that mediates many of the anti-inflammatory actions of glucocorticoids in models of acute (15) and chronic (16) inflammation including modulation of leukocyte trafficking (17, 18), ischemic damage (19), pain (20), and fever (21). Evidence for a functional link between annexin I and apoptosis has emerged (22, 23). On one hand, exogenous annexin I increases the rate of spontaneous PMN apoptosis (22), whereas endogenous annexin I is exported from the cytosol to the plasma membrane of apoptotic cells where it colocalizes with phosphatidylserine (PS), suggesting a role for annexin I in recognition of cell for phagocytic clearance (23). More recently, it has been reported that phagocytosis of apoptotic lymphocytes by MΦ was inhibited by pretreatment of either target cells or phagocytes with an Ab to annexin I, suggesting that annexin serves as both ligand and receptor in promoting phagocytosis (24).

In this study, we demonstrate that the peptide Ac2–26 promotes phagocytosis of apoptotic PMNs by human MΦ. We have investigated the underlying mechanisms, and we have explored whether the previously reported effect of dexamethasone (Dex) to enhance phagocytosis of apoptotic leukocytes (25, 26) could be attributed to Dex induction of annexin I expression.

Furthermore, we report that bone marrow-derived MΦ from annexin I-null mice are defective in clearance of apoptotic cells.

Materials and Methods

Materials

LXA4 was obtained from Biomol Research Laboratories. The annexin I mimetic peptide Ac2–26 (Ac-AMVSEFLKQAWFIENEEQEYVTQYK) was prepared by the Advance Biotechnology Centre (The Charing Cross and Westminster Medical School, London, U.K.) by using solid-phase
stepwise synthesis. Purity was >90% as assessed by HPLC and capillary electrophoresis (data supplied by manufacturer). A polyclonal sheep serum raised against the annexin 1-derived peptide Ac2–26 (LCPS1) that neutralizes the action of Dex and annexin 1 (27), was used as described by Perretti et al. (27). Adenosine 3′,5′-cyclic monophosphohosphate (Rp-cAMP) was obtained from Calbiochem (Nottingham, U.K.). 8-Bromoadenosine 3′,5′-cyclic monophosphate (8-BrcAMP) and Dex were obtained from Sigma-Aldrich. The antagonist Boc1 ((N-v-But-Phe-o-Leu-Phe-o-Leu-Phe) that blocks both the formyl-peptide receptor (FPR) and ALXR activation (13) was purchased from MP Biomedicals. Oregon Green phallolidin was from Molecular Probes. The TGF-β1, and IL-8 human ELISA kits were obtained from R&D Systems Europe. A rabbit anti-human annexin 1 Ab was from Zymed (Cambridge Biosciences).

Reagents were dissolved in DMSO or ethanol and further diluted in medium (final concentration, ≤0.1%). Equivalent concentrations of DMSO or ethanol were used as vehicle controls.

### Human leukocyte isolation

Human PMNs and monocytes were isolated from peripheral venous blood drawn from healthy volunteers, after informed written consent, as previously described (7, 9). Briefly, mononuclear cells were separated by centrifugation on Ficoll-Paque (Pharmacia) and plated at 2 × 10^6 cells/ml in RPMI 1640 (BioWhittaker) supplemented with 10% autologous serum, 2 mmol/L glutamine, 100 IU/ml penicillin, and 100 μg/ml streptomycin (Invitrogen Life Technologies). Lymphocytes were removed after 1-h culture, and Mφ were obtained by further culturing monocytes for 7 days.

For preparation of supernatant from Dex-treated Mφ, monocytes prepared as above were cultured for 5 days in RPMI 1640 supplemented with 10% serum in the presence or absence of 1 μM Dex. The supernatants were collected, centrifuged at 14,000 rpm for 10 min, and stored at −20°C.

PMNs, after dextran sedimentation (Dextran T500; Pharmacia) and hypotonic lysis of red cells, were suspended at 4 × 10^6 cells/ml. Spontaneous apoptosis was achieved by culturing PMNs in RPMI 1640 supplemented with 10% autologous serum, 2 mmol/L glutamine, 100 IU/ml penicillin, and 100 μg/ml streptomycin for 20 h at 37°C in 5% CO2 atmosphere. Cells were counted on average 25–50% apoptotic with <3% necrosis as assessed by light microscopy on stained cytospun preparations.

### Bone marrow-derived Mφ

Annexin 1-null mice and wild-type (WT) littermate controls were bred in house (28). All animals were fed on a standard chow pellet diet with free access to water and maintained on a 12-h light-dark cycle. Animal work was performed in accordance with Home Office regulations, Animals (Scientific Procedures) Act 1986.

WT and annexin 1-null mice (4–6 wk old) were killed, and the femurs were excised. The epiphyses were removed, and bone marrow was flushed from the bone before the marrow plugs being mechanically disrupted and washed (400 × g; 10 min). Cells were then resuspended in RPMI 1640 supplemented with 25 mM HEPES, 10% FCS, and 20% L929 conditioned medium, and incubated on plastic at 37°C. Fresh culture medium was added after 15 min at 37°C before coincubation with apoptotic PMNs as described above.

### Mφ phagocytosis of apoptotic PMNs

Human Mφ were treated with the appropriate stimuli as indicated for 15 min at 37°C. The treated cells were washed with RPMI 1640 before cocultivation with apoptotic PMNs (4 × 10^6 PMNs/well) at 37°C for 30 min. Mouse bone marrow-derived Mφ were exposed to human apoptotic PMNs at 37°C for 30 min. Noningested cells were removed by three washes with cold PBS. Phagocytosis was assessed by myeloperoxidase staining of cocultures fixed with 2.5% glutaraldehyde as previously reported (7). For each experiment, the number of Mφ containing one or more PMN in at least five fields (minimum of 400 cells) was expressed as a percentage of the total number of Mφ and an average between duplicate wells was calculated.

For inhibitor studies, Mφ were treated with the stable cell-permeable cAMP analog 8-Br-cAMP (2 mM), the protein kinase A (PKA) inhibitor Rp-cAMP (100 μM), or the neutralizing LCPS1 Ab (1/100) in the presence or absence of LXA4, or Ac2–26, or Dex-treated Mφ for 15 min at 37°C before coincubation with apoptotic PMNs as described above.

### Actin staining

Mφ on glass coverslips were incubated with vehicle or Ac2–26 peptide (32 μM) or supernatants from Dex-treated Mφ for 15 min at 37°C. In inhibitory studies, the neutralizing LCPS1 Ab (1/100) was coincubated with supernatants from Dex-treated Mφ. At the end of the incubations, cells were rinsed with PBS and fixed in 3.8% paraformaldehyde-PBS for 20 min at room temperature. Cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min and stained with Oregon Green-phallolidin (0.33 μmol/L) for 30 min at room temperature. Coverslips were mounted on microscope glass slides with Probing Antifade medium (Molecular Probes). Cells were viewed on an Axiovert 200M fluorescent microscope (Zeiss) using Axiosvision image analysis software (Imaging Associates).

### Western blotting

Supernatants from monocytes cultured for 5 days in the absence of Dex and supernatants from Dex-treated Mφ were resolved by electrophoresis on a 12% SDS polyacrylamide gel and transferred to Immobilon-P polyvinylidene difluoride membranes (Millipore). The membranes were incubated with blocking buffer (TBS [20 mMol/L Tris; 137 mMol/L NaCl] containing 0.1% Tween 20 [TBS-T] and 5% milk) before probing with a rabbit anti-annexin 1 (1/500 in TBS-T) Ab. After incubation with aHRP-conjugated anti-rabbit secondary Ab (1/2000 in TBS-T. New England Biolabs), bound Ab was visualized with an ECL detection system (Santa Cruz Biotechnology).

### Annexin depletion

The immunodepletion was conducted using polyclonal rabbit anti-annexin 1 (Cambridge Biosciences). Supernatants from Dex-treated Mφ were incubated overnight at 4°C with the primary Ab directed against annexin 1 or rabbit IgG (control), followed by protein G-agarose beads (Santa Cruz Biotechnology) for 2 h. The Aγ-Ab immune complexes were separated by centrifugation. The supernatants were collected, and immunoprecipitation was conducted two more times. Complete annexin 1 depletion was verified by Western blotting as described above.

### Cytokine production

TGF-β1, in acid-activated samples and IL-8 were assayed in supernatants from cocultures of Mφ and apoptotic PMNs by ELISA according to the manufacturer’s instruction. Supernatants from Mφ stimulated with 10 ng/ml LPS and coincubated with apoptotic PMNs for 18 h were used as positive controls.

### Statistical analysis

Statistical analysis was conducted using one-way ANOVA or unpaired Student’s t test with p < 0.05 for n independent samples being deemed statistically significant.

### Results

#### Peptide Ac2–26 stimulates Mφ phagocytosis of apoptotic PMNs coupled to rearrangement of actin cytoskeleton

Human monocyte-derived Mφ were exposed to the peptide Ac2–26 (32 μM; 15 min at 37°C) before addition of apoptotic human PMNs, and the extent of the ensuing phagocytosis was compared with that obtained with LXA4, previously shown to significantly enhance phagocytosis (7, 8). Pretreatment of Mφ with peptide Ac2–26 resulted in a significant increase of phagocytosis of apoptotic PMNs, with an effect comparable to that observed with LXA4 (1 μM; 15 min at 37°C) (control, 12.6 ± 1.5; LXA4, 21.8 ± 2.6%; Ac2–26, 20.7 ± 2.8%; p = 0.01 vs control; Fig. 1A). In addition, stimulation of Mφ with the peptide Ac2–26 caused F-actin rearrangement and modification in cell shape leading to cell polarization (Fig. 1B), suggesting that the peptide Ac2–26, similarly to the described effect of LXs, primed Mφ to a phagocytic state (3, 9).

Supernatants from Dex-treated Mφ contain annexin 1 and are associated with enhanced phagocytosis and actin rearrangement

As discussed above, annexin 1 protein is up-regulated by glucocorticoids to mediate some of their anti-inflammatory properties (15–21). We investigated the potential role of endogenous annexin 1 on phagocytosis of apoptotic cells by Mφ. Human monocytes were...
cultured for 5 days in the presence or absence of 1 μM Dex. Cell-free supernatants were collected and used to stimulate phagocytosis of apoptotic PMNs by Mφ.

Treatment of Mφ with supernatants from Dex-treated Mφ significantly enhanced phagocytosis of apoptotic PMNs compared with appropriate controls (vehicle; medium plus Dex incubated for 5 days without cells; supernatants from monocytes cultured for 5 days in the absence of Dex; Fig. 2A). Serial dilutions of the supernatants from Dex-treated Mφ showed that the effect on phagocytosis was linear with almost no changes in phagocytosis being observed with a 1/10 dilution (Fig. 2B). Fig. 2C shows that, similarly to the peptide Ac2–26, supernatants from Dex-treated Mφ induces actin rearrangement in Mφ, an effect reversed by coincubation with a neutralizing polyclonal Ab (LCPS1 diluted 1/100), that previously has been shown to neutralize the actions of Dex and annexin 1 (27).

The presence of annexin 1 in the supernatants from Dex-treated Mφ was assessed by Western blotting. Fig. 3A shows the presence of the characteristic annexin 1 doublet with the 34- and 37-kDa isoforms in the supernatants from Dex-treated Mφ. Annexin 1 was also detected in the supernatants from Mφ cultured for 5 days in the absence of Dex (Fig. 3A), but in lesser amounts and not in sufficient concentration to increase phagocytosis of apoptotic PMNs. The supernatants of Dex-treated Mφ were depleted of annexin 1 by three subsequent immunoprecipitations. Annexin 1-depleted supernatants failed to increase phagocytosis of apoptotic PMN by Mφ, indicating that annexin is responsible for the mechanism of action of the supernatant from Dex-treated Mφ (Fig. 3B).

The efficacy of our immunodepletion procedure was investigated by Western blotting (Fig. 3B, inset).

To further investigate the possibility that endogenous annexin 1 could mediate the stimulatory effect produced by the supernatants...
from Dex-treated MΦ, a neutralizing polyclonal Ab that has previously shown to neutralize the actions of Dex and annexin 1 (27). In our experimental conditions, the effect of Ac2–26 peptide as well as Dex-treated MΦ was nonphlogistic. MΦ were unstimulated (control) or treated with Ac2–26 (32 μM) or supernatants from Dex-treated MΦ for 15 min at 37°C before coincubation with apoptotic PMNs. After 30 min, supernatants were collected and TGF-β1 and IL-8 production was measured by ELISA. Data are expressed as fold of induction on basal value; mean ± SEM (n = 4); ∗, p < 0.05 vs unstimulated MΦ.

FIGURE 3. Supernatants from Dex-treated MΦ contain annexin 1. A, Supernatants from MΦ treated with Dex (1 μM) and supernatants from monocytes cultured for 5 days in the absence of Dex were resolved by electrophoresis on a 12% SDS-polyacrylamide gel, and Western blot analysis was performed with an Ab against annexin 1. A representative blot of n = 3 is shown. B, Supernatants from Dex-treated MΦ were depleted of annexin by immunoprecipitation with an Ab direct against annexin 1. Complete annexin 1 depletion was verified by Western blotting and showed in the inset. MΦ were exposed to annexin-depleted supernatant for 15 min before coincubation with apoptotic PMNs for 30 min. Data are expressed as percentage of phagocytosis ± SEM (n = 3). C, MΦ were treated with anti-annexin 1 Ab (LCPS1 diluted 1/100) in the absence (control) or in the presence of supernatants from Dex-treated MΦ or Ac2–26 peptide (15 min at 37°C) and then coincubated with apoptotic PMNs for 30 min. Data are expressed as fold of induction over control; mean ± SEM (n = 3); ∗, p < 0.05 vs absence of LCPS1.

Phagocytosis of apoptotic PMNs induced by Ac2–26 peptide and by supernatants from Dex-treated MΦ is coupled to TGF-β release with a concomitant decrease in IL-8 production

Phagocytosis of apoptotic cells may contribute to the resolution of inflammation being coupled with TGF-β1 release and not associated with the release of proinflammatory cytokines such as IL-8 and MCP-1 (4, 5, 7, 8). To investigate whether annexin-mediated phagocytosis might promote the resolution of inflammation, unstimulated MΦ (control) or treated with peptide Ac2–26 or supernatants from Dex-treated MΦ (15 min) were exposed to apoptotic PMNs, and the cytokine levels were quantified in the supernatants by ELISA. As previously described (4), in our experimental conditions, levels of TGF-β1 produced by unstimulated MΦ in the absence of apoptotic cells were low (data not shown). Ac2–26 peptide or supernatants from Dex-treated MΦ treatment induced a further significant increase in TGF-β1 levels after 30-min coincubation with apoptotic PMNs compared with control (Fig. 4). In contrast, Ac2–26 peptide or supernatants from Dex-treated MΦ treatment caused a further slight decrease in IL-8 production compared with unstimulated MΦ that had ingested apoptotic PMNs (Fig. 4); whereas the positive control (MΦ stimulated with LPS) induced a 20-fold increase in IL-8 release.

Annexin-stimulated phagocytosis of apoptotic PMNs is blocked by the FPR antagonist Boc1 and is cAMP/PKA sensitive

It has recently been demonstrated that full-length annexin 1 and its bioactive peptides interact with the LX receptor ALXR/FPRL1 (12, 13, 29). In our experimental conditions, the effect of Ac2–26 (32 μM) on the uptake of apoptotic PMNs was not additive with a suboptimal (10–12 M) ineffective concentration of LXA4 (vehicle, 11.5 ± 1.7; LXA4, 13.08 ± 1.9; Ac2–26, 18.6 ± 1.7∗; LXA4 plus Ac2–26, 14.6 ± 1.1; percentage of phagocytosis ± SEM; n = 3; ∗, p < 0.05 vs vehicle). These data suggest that the annexin effect on phagocytosis could be mediated by the ALXR/FPRL1 receptor. To address this possibility further, we used the Boc1 compound, an antagonist to this receptor previously shown to antagonize the effects of the peptide Ac2–26, on human neutrophils (29, 30). In our experimental conditions, the stimulating effect of either peptide Ac2–26 or endogenous annexin 1 (present in the supernatants from Dex-treated MΦ) on phagocytosis of apoptotic PMNs was significantly inhibited by Boc1 (Fig. 5). The antagonist was equally effective on the response elicited by LXA4. Together, these data indicate a relevant function for the ALXR/FPRL1 receptor in this specific MΦ response.

The cAMP/PKA pathway is one of the signal transduction pathways better characterized in the phagocytosis of apoptotic PMNs (31). Consistent with our previous results for LXs (7), in this study,
Data are expressed as percentage of M of cAMP and PKA was quantified as described in.

To investigate the direct involvement of M in defective phagocytosis of apoptotic PMNs, Bone marrow-derived M pathways. Inhibition of the effects of peptide Ac2–26 and of the Dex-treated M was quantified as described in Materials and Methods. Data are expressed as percentage of M staining positively for myeloperoxidase. Data are mean ± SEM of n = 6 performed with n = 2 mice. *, p < 0.01 vs WT M.

**Table 1.** Annexin-induced phagocytosis of apoptotic PMNs by M: role of cAMP and PKA

<table>
<thead>
<tr>
<th></th>
<th>% Phagocytosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>11.2 ± 1.5</td>
</tr>
<tr>
<td>Ac2–26</td>
<td>20.4 ± 3.3*</td>
</tr>
<tr>
<td>Supernatant from Dex-treated M</td>
<td>15.4 ± 1.6*</td>
</tr>
<tr>
<td>8-Br-cAMP + vehicle</td>
<td>12.4 ± 3.4</td>
</tr>
<tr>
<td>Br-cAMP + Ac2–26</td>
<td>11.0 ± 1.0</td>
</tr>
<tr>
<td>Br-cAMP + supernatant from Dex-treated M</td>
<td>10.6 ± 2.2</td>
</tr>
<tr>
<td>Rp-cAMP + vehicle</td>
<td>18.2 ± 2.3*</td>
</tr>
<tr>
<td>Rp-cAMP + Ac2–26</td>
<td>17.6 ± 1.1*</td>
</tr>
<tr>
<td>Rp-cAMP + supernatant from Dex-treated M</td>
<td>19.8 ± 1.0*</td>
</tr>
</tbody>
</table>

* Mean ± SEM (n = 4).

**Discussion**

There is growing appreciation that the resolution of inflammation is a dynamically regulated process that may provide several opportunities for therapeutic intervention (6). In this regard, it is noteworthy that the biosynthesis of specific mediators that actively promote the resolution of inflammation has been demonstrated (10, 11, 32). An important component of effective host defense requires leukocyte trafficking to a site of inflammation where they perform their specialized roles. Subsequent to apoptosis, it is vital that effete leukocytes are cleared by nonphlogistic phagocytosis, sparing tissue from exposure to the noxious and immunogenic contents of necrotic cells. Dysregulated clearance of apoptotic cells has been proposed to contribute to pathogenesis of several chronic inflammatory conditions including systemic lupus erythematosus and rheumatoid arthritis (3). Immune-suppressive glucocorticoids such as Dex are typically used in the therapeutic regimens for such conditions.

In the present study, we report the novel finding that anti-inflammatory peptide Ac2–26 (corresponding to the first amino acids of the annexin 1 N terminus) and endogenous annexin 1 released by Dex-treated M promote the nonphlogistic phagocytosis of apoptotic PMNs. In addition, we demonstrate that bone marrow-derived M isolated from annexin 1-null mice present a defective phagocytosis of apoptotic PMNs.

Annexin 1 was originally identified as a mediator of many of the anti-inflammatory actions of glucocorticoids (15, 16). However, it has been shown that annexin mimics the anti-inflammatory actions of glucocorticoids in many experimental models of inflammation (33), block leukocyte migration (17, 18), inhibit eicosanoid synthesis (34), and induce apoptosis (22). Autoantibodies against annexin 1 may be responsible for some forms of glucocorticoid resistance in association with autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis (35, 36). A role for endogenous annexin in phagocytosis of apoptotic cells has been hypothesized by the observation that annexin 1 is exported from the cytosol to the plasma membrane of apoptotic Jurkat cells where it colocalizes with PS in discrete patches (23). The exposure of annexin 1 is required for the clustering of the PS receptor, and it is necessary for an efficient recognition and internalization of apoptotic cells by endothelial cells, suggesting a role for annexin 1 as a bridging molecule of PS on apoptotic cells to phagocytes (23). In addition, a role for M surface expression of annexins 1 and II has recently been reported (24). Furthermore, recent work with cells taken from annexin 1-null mice indicate that lack of annexin 1 is functionally associated with a reduced capacity of the M to phagocytose nonopsonized zymosan particles (37).

It was therefore of interest to us to investigate whether exogenous and endogenous annexin 1 could modulate phagocytosis of apoptotic cells and the underlying mechanisms. In the present study, we report that the peptide Ac2–26 may have a role in the resolution of inflammation by promoting the nonphlogistic phagocytosis of apoptotic PMNs. This effect is coupled to TGF-β release and to changes in F-actin reorganization in M. Given that

![FIGURE 6. Annexin 1-null M are defective in phagocytosis of apoptotic PMNs. Bone marrow-derived M from WT or annexin 1-null mice were incubated with human apoptotic PMNs for 30 min. Phagocytosis was quantified as described in Materials and Methods. Data are expressed as percentage of M staining positively for myeloperoxidase. Data are mean ± SEM of n = 6 performed with n = 2 mice. *, p < 0.01 vs WT M.](image-url)
the process of phagocytosis is highly dependent on the localized polymerization of actin filaments that facilitate the formation of podosomes that surround the cells or the microorganisms to be engulfed (38), it can be suggested that the effect of Ac$_{2-26}$ on actin cytoskeleton might prime Mϕ to a phagocytic phenotype, contributing to the potential role of peptide Ac$_{2-26}$ in promoting phagocytosis.

Resting Mϕ contain high levels of annexin 1 (39), which is rapidly externalized by glucocorticoid treatment (39–41). Similarly, the monocytic cell line U937 expresses increased amount of endogenous annexin 1 during differentiation by phorbol ester, and subsequent glucocorticoid treatment results in translocation of annexin 1 to the external surface and its release into the medium (42, 43). In this study, we present evidence that the endogenous annexin released by Dex-treated Mϕ displays a phagocytic effect of apoptotic cells. The effect of supernatants from Dex-treated Mϕ was mediated specifically by annexin and not by Dex itself present in the medium, because the controls prepared with medium containing serum and Dex failed to increase phagocytosis. We also demonstrated that LCPS1, a neutralizing Ab raised against the N-terminal peptide of annexin 1 (27), abrogated the enhancing effect of supernatant from Dex-treated Mϕ. Basal phagocytosis was only slightly affected by LCPS1 Ab (−16%). Interestingly, Fan et al. (24) have demonstrated that phagocytosis of apoptotic lymphocytes by J744 cells or elicited peritoneal Mϕ can be blocked by an anti-annexin 1 Ab. We have showed that immunodepletion of annexin 1 from the supernatants of Dex-treated Mϕ by immunoprecipitation abolished the stimulating effect on phagocytosis. For immunodepletion, we use a rabbit polyclonal Ab that recognized the full-length annexin 1 and that is well characterized for Western blotting according to the manufacturer’s details, but not for neutralizing effect. On the contrary, the LCPS1 Ab is a polyclonal sheep serum raised against the annexin 1-derived peptide Ac$_{2-26}$ that neutralizes the action of Dex and annexin 1 (27). In aggregate, these data support the hypothesis that endogenous annexin is the mediator responsible for the phagocytic effect, suggesting that Mϕ-derivated annexin 1 could be one of the mechanisms responsible for glucocorticoid facilitation of the uptake of apoptotic PMNs, eosinophils, and lymphocytes (25, 26). We cannot exclude the possibility that LCPS1 neutralizes Ac$_{2-26}$ peptide generated by proteolysis of annexin 1 in the supernatants of Dex-treated Mϕ and that Ac$_{2-26}$ peptide is responsible for the stimulation of phagocytosis. However, it has been shown that the annexin 1 mimetics (shorter peptide sequences from the N-terminal region of the protein, i.e., Ac$_{2-26}$) share some of the anti-inflammatory action of annexin 1 (12, 16, 19, 29). Hannon et al. (28) have recently generated a mouse line deficient in annexin 1. These mice are more prone to inflammatory responses in models of acute (28, 44) and chronic (45) inflammation. In addition, peritoneal Mϕ deficient in annexin 1 display a stimulus-dependent alteration in phagocytosis of insoluble stimuli; for instance, defect in the ingestion of non-opsonized, but not of opsonized, zymosan was evident (37). In this study, we have used bone marrow Mϕ in a heterologous system with human PMNs, as previously described (8, 25, 46, 47), to determine the role for endogenous annexin 1. In line with the neutralizing experiments, bone marrow-derived Mϕ from annexin 1-null mice had a reduced phagocytic activity indicating a physiological role of endogenous annexin 1. These data are consistent with a role for endogenous Mϕ annexin in facilitating phagocytosis of apoptotic leukocytes as described by Fan et al. (24). We can therefore propose that at least part of the anti-inflammatory effects lost by Dex, and possibly other glucocorticoids, when the later stages of the inflammatory responses are investigated in annexin 1-null mice (44, 45), could be due to a defective removal of apoptotic cells, hence to a malfunctioning healing process.

Recent investigations conducted predominantly with human neutrophils have indicated an involvement of the receptor for formylated peptides, termed FPR, and its analog FPRL1 (or ALXR, because it is the receptor for the endogenous ligand LXA$_4$) in the in vitro inhibitory actions of annexin 1 and its peptidometics (13, 29). LXA$_4$ and annexin 1 and its bioactive peptides converge on ALXR to down-regulate PMN recruitment to inflammatory loci (13). Results in the same study suggested that the peptide Ac$_{2-26}$ and LXA$_4$ can share some intracellular signaling pathways in PMNs (13). In the mouse, the anti-adhesive and anti-inflammatory actions of peptide Ac$_{2-26}$ on PMNs are mediated by a Boc-1-sensitive receptor, distinct from FPR (12). In the present paper, we report that LXA$_4$ and annexin-stimulated phagocytosis of apoptotic PMNs was inhibited by a pan-FPR/ALXR antagonist, Boc1, suggesting the involvement of a common receptor mechanism. Annexin 1 colocalizes with PS on the cell membrane of apoptotic cells (23), and it has been hypothesized that, when annexin 1 (or possibly annexin II) is bound to PS on the target cells, it can potentially bind to annexin receptor on the Mϕ surface or function as bridging molecule (24). We cannot rule out the possibility that annexin acts as a bridging molecule; however, our findings with Boc1 and the lack of additivity of the effect of peptide Ac$_{2-26}$ and Dex-treated Mϕ-stimulated phagocytosis was inhibited by cell-permeable 8-Br-cAMP and mimicked by a PKA inhibitor, suggesting a modulatory role for intracellular cAMP also in the annexin-stimulated phagocytosis.

In conclusion, we report for the first time that a peptidomimetic of annexin 1 promotes phagocytosis of apoptotic cells acting through the ALXR receptor and stimulating F-actin reorganization in Mϕ. Such an effect could be translated to the endogenous protein, because this phagocytic effect was observed when endogenous annexin was released by Dex-treated Mϕ and was markedly attenuated in cells prepared from annexin 1-null mice. Altogether, these novel actions expand and strengthen the role for annexin 1 as a proresolution mediator of the inflammatory milieu.

Acknowledgment
We thank Dr. Cormac Taylor for helpful discussion.

Disclosures
The authors have no financial conflict of interest.

References


